Optical coherence tomography-based intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration

被引：7

作者：

Ernst B.J. ^{[1
]}

Barkmeier A.J. ^{[2
]}

Akduman L. ^{[1
]}

机构：

[1] Saint Louis University Eye Institute, St. Louis, MO 63104

[2] Cullen Eye Institute, Baylor College of Medicine, Houston, TX

来源：

International Ophthalmology | 2010年 / 30卷 / 3期

关键词：

Age-related macular degeneration; Choroidal neovascularization; Optical coherence tomography; Ranibizumab;

D O I：

10.1007/s10792-009-9324-9

中图分类号：

学科分类号：

摘要：

To evaluate optical coherence tomography (OCT)-based intravitreal ranibizumab treatment for neovascular age-related macular degeneration (AMD), the charts of consecutive patients who received intravitreal ranibizumab for subfoveal choroidal neovascularization due to AMD were retrospectively reviewed. Patients with less than 6 months follow-up were excluded. OCT was performed at baseline and at monthly intervals for induction therapy. Injections were given monthly until no improvement was observed between successive OCTs. In the maintenance period, reinjections were performed for any recurrence of macular fluid on OCT. Main outcome measures were visual acuity and number of injections given. Twenty-five eyes of 22 patients with mean follow-up of 16 months [standard deviation (SD) = 3.7 months] had mean improvement of 1.6 lines of Snellen visual acuity (SD 2.9, 95% confidence interval 0.48-2.9, P = 0.008). Visual acuity was stable (≤3 lines of visual acuity lost) in 22 eyes (88%). Nine eyes (36%) gained ≥3 lines. Three eyes (12%) lost ≥3 lines. A mean of 6.0 (SD 2.7) injections were given over a follow-up period ranging from 8 to 21 months. We conclude that OCT-based intravitreal ranibizumab treatment for neovascular AMD offered excellent visual acuity results and reduced the number of injections compared with monthly dosing. © Springer Science+Business Media B.V. 2009.

引用

页码：267 / 270

页数：3

共 7 条

[1]

Rosenfeld P.J., Brown D.M., Heier J.S., Et al., Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, pp. 1419-1431, (2006)

[2]

Brown D.M., Kaiser P.K., Michels M., Et al., Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, 355, pp. 1432-1444, (2006)

[3]

Chen Y., Wiesmann C., Fuh G., Et al., Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen, J Mol Biol, 293, pp. 865-881, (1999)

[4]

Regillo C.D., Brown D.M., Abraham P., Et al., Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J Ophthalmol, 145, pp. 239-248, (2008)

[5]

Fung A.E., Lalwani G.A., Rosenfeld P.J., Et al., An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration, Am J Ophthalmol, 143, pp. 566-583, (2007)

[6]

Kaiser P.K., Blodi B.A., Shapiro H., Acharya N.R., MARINA study group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration, Ophthalmology, 114, pp. 1868-1875, (2007)

[7]

Falkenstein I.A., Cochran D.E., Azen S.P., Et al., Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts, Ophthalmology, 115, pp. 319-323, (2008)

← 1 →